Mucosis B.V. is a Dutch biotechnology company developing innovative mucosal vaccines that can be applied needle-free via the nose or mouth. Mucosis’s lead product candidate is FluGEM™, an intranasal vaccine to prevent influenza. Our vaccines are based on the patented Mimopath™ technology. This technology enables a more natural immune response as well as a broad base of protection.
| Website | http://www.mucosis.com |
| Revenue | $16 million |
| Employees | 2 (0 on RocketReach) |
| Founded | 2006 |
| Address | 1 L.j. Zielstraweg Groningen 04, Gx 9713, NL |
| Phone | +31 50 820 0050 |
| Technologies | |
| Industry | Biotechnology, Business Services General, Business Services, Science and Engineering, Drug Discovery, Health Care, Medical |
| Keywords | Influenza Vaccine, Immunology, Vaccine Technology, Biotechnology, Drug Delivery, Pharmaceutical, Immunotherapy, Prevention, Therapeutics, Clinical Trials, Health, Medicine, Research, Development |
| Competitors | Novartis, Merck & Co., Inc., Pfizer, Sanofi, GSK, AstraZeneca +47 more (view full list) |
| SIC | SIC Code 28 Companies, SIC Code 283 Companies |
| NAICS | NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies, NAICS Code 32541 Companies, NAICS Code 325414 Companies |
Looking for a particular Mucosis employee's phone or email?
Mucosis Questions
The Mucosis annual revenue was $16 million in 2026.
The NAICS codes for Mucosis are [3254, 325, 32, 32541, 325414].
The SIC codes for Mucosis are [28, 283].
Related Companies
G2Crowd Trusted
300K+
Plugin Users
